3-((1S)-1-(1,3-benzodioxol-5-yl)-2-{[(2-methoxy-4-methylphenyl)sulfonyl]amino}-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-((1S)-1-(1,3-benzodioxol-5-yl)-2-{[(2-methoxy-4-methylphenyl)sulfonyl]amino}-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid
• 英文别名: S-(+)-3-{1-(1,3-benzodioxol-5-yl)-2-[(2-methoxy-4-methylphenyl)sulfonylamino]-2-oxoethyl}-1-methyl-1H-indole-6-carboxylic acid；(s)-(+)-3-{1-(1,3-Benzodioxol-5-yl)-2-[(2-methoxy4-methylphenyl)-sulfonylamino]-2-oxoethyl}-1-methyl-1h-indole-6-carboxylic acid；3-[(1S)-1-(1,3-benzodioxol-5-yl)-2-[(2-methoxy-4-methylphenyl)sulfonylamino]-2-oxoethyl]-1-methylindole-6-carboxylic acid
• 化学式: C₂₇H₂₄N₂O₈S
• 分子量: 536.562
• InChiKey: RXNZJEAMURXNLG-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  142
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-((1S)-1-(1,3-benzodioxol-5-yl)-2-{[(2-methoxy-4-methylphenyl)sulfonyl]amino}-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.08h， 生成 (S)-(+)-2-(6-hydroxymethyl-1-methyl-1H-indol-3-yl)-N-[(2-methoxy-4-methylphenyl)sulfonyl]-2-(3,4-methylenedioxyphenyl)acetamide
  参考文献：
  名称：

  An Efficient and Scalable Synthesis of the Endothelin Antagonists UK-350,926 and UK-349,862 Using a Dynamic Resolution Process

  摘要：

  The development and scale-up of a potential manufacturing route to the endothelin antagonists UK-350,926 1 and UK-349,862 2 are described. A key synthetic challenge in designing an efficient route to these molecules was the optical lability of the stereogenic centre during the construction of the acylsulfonamide functionality. In the discovery synthesis of UK-350,926 the chiral centre was introduced by classical resolution and the acylsulfonamide functionality synthesized by construction of the N-sulfonyl bond. An alternative more efficient process route was developed involving the preparation of racemic UK-350,926 and final step dynamic resolution with (S)-(-)-1-phenylethylamine as the key step. The process route prepared the acylsulfonamide by construction of the N-carbonyl bond, eliminates a cryogenic reaction and a hazardous intermediate from the synthesis, improves the overall process yield, and allows access to both endothelin antagonists from common intermediates without the need for purification by chromatography. Full experimental details of the new five-step process to prepare UK-349,862 from commercially available starting materials are given for the first time.

  DOI：

  10.1021/op050102f
• 作为产物：
  描述：

  2-(1,3-benzodioxol-5-yl)-2-bromoacetic acid 在 盐酸 、 N-羟基-7-氮杂苯并三氮唑 、 5%-palladium/activated carbon 、 R(+)-alpha-甲基苄胺 、 氢气 、 sodium hexamethyldisilazane 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， -60.0~90.0 ℃ 、413.7 kPa 条件下， 反应 6.17h， 生成 3-((1S)-1-(1,3-benzodioxol-5-yl)-2-{[(2-methoxy-4-methylphenyl)sulfonyl]amino}-2-oxoethyl)-1-methyl-1H-indole-6-carboxylic acid
  参考文献：
  名称：

  An Efficient and Scalable Synthesis of the Endothelin Antagonists UK-350,926 and UK-349,862 Using a Dynamic Resolution Process

  摘要：

  The development and scale-up of a potential manufacturing route to the endothelin antagonists UK-350,926 1 and UK-349,862 2 are described. A key synthetic challenge in designing an efficient route to these molecules was the optical lability of the stereogenic centre during the construction of the acylsulfonamide functionality. In the discovery synthesis of UK-350,926 the chiral centre was introduced by classical resolution and the acylsulfonamide functionality synthesized by construction of the N-sulfonyl bond. An alternative more efficient process route was developed involving the preparation of racemic UK-350,926 and final step dynamic resolution with (S)-(-)-1-phenylethylamine as the key step. The process route prepared the acylsulfonamide by construction of the N-carbonyl bond, eliminates a cryogenic reaction and a hazardous intermediate from the synthesis, improves the overall process yield, and allows access to both endothelin antagonists from common intermediates without the need for purification by chromatography. Full experimental details of the new five-step process to prepare UK-349,862 from commercially available starting materials are given for the first time.

  DOI：

  10.1021/op050102f

文献信息

• Enantioselective Synthesis of Tertiary α,α-Diaryl Carbonyl Compounds Using Chiral <i>N,N′</i>-Dioxides under Umpolung Conditions
  作者：Tae-Woong Um、Girim Lee、Seunghoon Shin

  DOI：10.1021/acs.orglett.0c00333

  日期：2020.3.6

  addition of the chiral N,N'-dioxide into ynamides generated enolonium ions in situ which underwent enantioselective alkylation by indoles, pyrroles, and phenols, without racemization of the formed tertiary center. This external oxidant approach allows for the use of unmodified nucleophiles and does not leave trace groups from the oxidant, which significantly increases the synthetic efficiency and the

  布朗斯台德酸催化的手性N，N'-二氧化物加成到酰胺中，生成原位的en离子，该离子通过吲哚，吡咯和苯酚进行对映选择性烷基化，而没有消旋形成的叔中心。这种外部氧化剂方法允许使用未修饰的亲核试剂，并且不会从氧化剂中留下痕量基团，从而显着提高了合成效率和产物多样性。此外，N，N'-二氧化物的副产物可以有效地再循环成光学纯的形式。
• Indole derivatives useful in therapy
  申请人：Pfizer Inc.

  公开号：US06211223B1

  公开（公告）日：2001-04-03

  The invention provides S-(+)-3-{1-(1,3-benzodioxol-5-yl)-2-[(2-methoxy-4-methylphenyl)sulfonylamino]-2-oxoethyl}-1-methyl-1H-indole-6-carboxylic acid, which is substantially free from its (R)-(−)-enantiomer, and pharmaceutically acceptable derivatives thereof. The compounds are useful in the treatment of inter alia acute renal failure, restenosis and pulmonary hypertension.

  这项发明提供了S-（+）-3- 1-（1,3-苯并二氧杂环戊-5-基）-2-[(2-甲氧基-4-甲基苯基)磺酰氨]-2-氧乙基}-1-甲基-1H-吲哚-6-羧酸，该化合物基本上不含其（R）-（-）-对映体，以及其药学上可接受的衍生物。这些化合物在治疗急性肾衰竭、再狭窄和肺动脉高压等方面是有用的。
• [EN] INDOLE DERIVATIVE USEFUL AS ENDOTHELIN RECEPTOR ANTAGONIST<br/>[FR] DERIVE INDOLIQUE UTILE COMME ANTAGONISTE DE RECEPTEUR D'ENDOTHELINE
  申请人：PFIZER LIMITED

  公开号：WO1999020623A1

  公开（公告）日：1999-04-29

  (EN) The invention provides S-(+)-3- 1-(1,3-benzodioxol -5-yl)-2-[ (2-methoxy-4- methylphenyl)sulfonylamino] -2-oxoethyl }-1-methyl -1$i(H)-indole- 6-carboxylic acid, represented by formula (a), which is substantially free from its (R)-(-)-enantiomer, and pharmaceutically acceptable derivatives thereof. The compound is useful in the treatment of $i(inter alia) acute renal failure, restenosis and pulmonary hypertension.(FR) L'invention concerne un acide S-(+)-3- 1,3-benzodioxol -5-yl)-2-[ (2-méthoxy-4- méthylphényl)sulfonylamino] -2-oxoéthyl }-1-méthyl -1$i(H)-indole- 6 carboxylique représenté par la formule (a) qui est sensiblement exempt de son (R)-(-)-énantiomère et ses dérivés pharmaceutiquement acceptables. Les composés sont utiles dans le traitement notamment d'insuffisance rénale aiguë, de resténose et d'hypertension pulmonaire.

  该发明提供了由式(a)表示的S-(+)-3- 1-(1,3-苯并二氧杂环-5-基)-2-[ (2-甲氧基-4-甲基苯基)磺酰胺]-2-氧代乙基 }-1-甲基-1$i(H)-吲哚-6-羧酸，其基本上不含其(R)-(-)-对映体及其药学可接受的衍生物。该化合物在治疗急性肾功能衰竭、再狭窄和肺动脉高压等方面具有用途。
• Therapeutic treatments using centhaquin
  申请人：MIDWESTERN UNIVERSITY

  公开号：US10828368B2

  公开（公告）日：2020-11-10

  Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans.

  公开了使用肾上腺素能制剂（如仙人掌）治疗高血压、疼痛和抢救失血性休克的方法。这些方法可治疗哺乳动物，包括人类。
• Racemisation-free synthesis of chiral acylsulfonamides
  作者：David Ellis

  DOI：10.1016/s0957-4166(01)00259-2

  日期：2001.7

  The development and application of a synthesis of acylsulfonamide A avoiding racemisation of the labile benzylic stereogenic centre is described. (C) 2001 Elsevier Science Ltd. All rights reserved.